We are an emerging commercial-stage company focused on the development and commercialization of innovative gene signature-based diagnostic tests, which assist healthcare professionals in making personalized treatment decisions for individual patients. These tests are designed to accurately determine the type or status of the disease or to predict a patient’s response to a specific treatment. Based on the test results, healthcare professionals can tailor the treatment to the individual patient.
This science of so-called ‘personalized medicine’ will improve the survival and quality of life for the individual patient as it has the potential to:
- Select the right treatment for the right patient at the right moment;
- Minimize unnecessary treatment;
- Reduce the level of adverse drug reactions; and
- to ultimately improve health outcomes by increasing the effectiveness of treatment for the individual patient.
Our Profiler™ platform makes centralized data analysis possible on a worldwide basis by any local laboratory, provided that the local laboratory is equipped with widely-used and standard equipment. In order to run our diagnostic tests, local laboratories must install a test-specific software module (that we have developed and provide) on their Affymetrix DX2 Gene scanning equipment and establish a secured gateway connection with our Profiler™ platform. Running our diagnostic tests, such as the MMprofiler™, therefore do not require substantial investment for data analysis capacity, nor assay validation efforts, significant changes in operating procedures or particular staff training by the local laboratories. Once the above steps are completed, a local laboratory can process a sample itself and generate the raw genetic data at the workstation. Our Profiler™ platform is scalable and can support the implementation and commercial roll-out of our future diagnostic tests.
At SkylineDx, we are committed to build a world class diagnostics company that is strategically focused on the broad expansion of our current and future gene signature-based diagnostic tests. It is our mission to improve the quality of life of patients by enabling patients to benefit sooner and be treated safer from new insights at the elementary genetic level of their disease.
SkylineDx Management Team
Dharminder Chahal, MSc - Chief Executive OfficerRead biography
Pim van Bruggen, MBA - EVP FinanceRead biography
Nicky Rijk-Vogels, MSc - EVP Global Business DevelopmentRead biography
Martin van Vliet, MSc, PhD - EVP Bioinformatics & Product DevelopmentRead biography
Dharminder Chahal, MSc - Chief Executive Officer
Mr. Chahal has served as the Chief Executive Officer and founding partner since the inception of SkylineDx in August 2013. He is also currently the Chief Executive Officer at Quorics (formerly known as CardioGenx), Managing Director at Exponential BV, and Fund Manager at Swanbridge Capital. Mr. Chahal has extensive board experience in the life sciences in current and previous (observer) board roles at at Agendia, Bioinvent, DCPrime, deVGen, Innate Pharma, Isobionics, Octoplus and VitalneXtIn addition, Mr. Chahal brings with him a great deal of experience in the private equity sector as an investment manager at Nationaal Grondbezit (part of the van Herk Group), private equity investor at Robeco Alternative Investments, and an associate at Kempen & Company. Mr. Chahal received his MSc cum laude degree from the University of Delft, The Netherlands, in aerospace engineering and an MSc degree from the University of Rotterdam, The Netherlands, in business economics.
Pim van Bruggen, MBA - EVP Finance
Mr. van Bruggen joined SkylineDx in March, 2017 and currently serves the company as the EVP Finance. He brings with him significant experience in finance, accounting, and due diligence. Most recently he was the finance director for De Poli Tankers. Prior to that he worked with PricewaterhouseCoopers (PwC) in the Netherlands, Norway, and the USA. During his tenure at PwC, he primarily focused his efforts on managing the due diligence processes for both corporations and private equity firms that resulted in the mergers and/or acquisitions of international public and private businesses. He was also directly involved in successful IPO’s. During his career, Pim held various financial management positions with several other international growth companies. He holds a CPA degree from Erasmus University Rotterdam, the Netherlands and an MBA degree from Derbyshire University, England.
Nicky Rijk-Vogels, MSc - EVP Global Business Development
Mrs. Rijk-Vogels joined SkylineDx in November 2014 to manage the company’s business development efforts. Nicky transitioned to her new role as the Executive Vice President, Global Business Development for SkylineDx in July 2016. Nicky has a proven track record in the establishment of (public-private) partnerships, the commercialization of new technologies, deal making, spin-off creation, and intellectual property management that she obtained in various business development roles in a diverse range of biotechnology organizations. After several years in the technology transfer offices of leading academic institutions, she moved to a commercial biotech role in business development with a startup company. Nicky has significant experience with patent applications and has been directly involved in more than 50 successful licensing and/or collaboration projects. In addition, she has been involved in nearly a dozen spin-off companies on their path to successful commercialization. Nicky holds an MSc degree in Science and Innovation Management from the University of Utrecht and a minor in Private Law.
Martin van Vliet, MSc, PhD - EVP Bioinformatics & Product Development
Dr. van Vliet joined SkylineDx when it was founded in September 2013 where he was responsible for managing the company’s bioinformatics initiatives. He transitioned to his new role as Executive Vice President, Bioinformatics and Product Development in July 2016 where he currently heads all bioinformatics and product development activities. Prior to this he was responsible for bioinformatics at Skyline Diagnostics from 2009 to 2013. Martin has extensive knowledge in the bioinformatics field and brings more than ten years of experience analyzing big-data from various genomics platforms, including microarrays and Next Generation Sequencing. He has a proven track record developing CE-IVD marked tests and is a named inventor on multiple patents. In addition, he is an author on more than 15 peer-reviewed publication as well as numerous oral/poster presentations at international meeting. He holds a PhD degree in Bioinformatics from the Netherlands Cancer Institute / University of Delft, as well as an MSc degree in Electrical Engineering from the University of Delft, The Netherlands.
Background and History
The era of personalized medicine
In June 2015, we acquired a new gene signature-based research pipeline in the cardiovascular disease field from CardioGenx which is forming the basis of our development of the APprofiler™.
Who we are
We are an emerging commercial stage company focused on the development and commercialization of innovative gene signature-based diagnostic tests, which assist healthcare professionals in making personalized treatment decisions for individual patients.